Table 1.
Cohort characterization (n=251)
| Mean (SD) | Range | Proportion of Cohort (%) | |
|---|---|---|---|
| Age (years) | 44.1 (7.9) | 23–67 | |
| Education (years) | 13.0 (2.3) | 7–18 | |
| Global Deficit Score (GDSa) | 0.39 (0.5) | 0–3.5 | |
| CD4 nadir (per mm3) | 190.2 (183.3) | 0–1104 | |
| Current CD4 (per mm3) | 479.0 (262.0) | 7–1716 | |
| Estimated Months Seropositive | 132 (74) | 7–285 | |
| Estimated Cumulative Months on ART | 67 (55) | 0–215 | |
| Ethnicity | Caucasian | 42 | |
| African American | 45 | ||
| Hispanic | 10 | ||
| Other | 3 | ||
| Sex | 82 (male) | ||
| Neurocognitively Impaired | 37 | ||
| Detectable HIV RNA in CSF | 29 | ||
| Detectable HIV RNA in Plasma | 49 | ||
| ART History | Currently Using | 76 | |
| Past Use | 14 | ||
| Never Used | 10 | ||
| CDC Stage | |||
| CDC-A | 34 | ||
| CDC-B | 28 | ||
| CDC-C | 38 | ||
| AIDS | 66 | ||
| HCV Coinfection | 25 |
a
Criterion for Neurocognitive Impairment is a Global Deficit Score of greater than 0.5